{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:35:45Z","timestamp":1777599345943,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Voriconazole is primarily metabolized by CYP2C19 and CYP3A4. Drug interactions that affect this pathway can alter its plasma exposures, resulting in untargeted voriconazole concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>In this case report, we describe the case of a 64-year-old man who was treated for non-Hodgkin\u2019s lymphoma with continuous glucocorticoids co-administrated with voriconazole against invasive pulmonary aspergillosis. A decrease in trough concentration (C<jats:sub>min<\/jats:sub>) of voriconazole was observed and related with co-administration of dexamethasone in the patient carrying the CYP2C19 *1*2 genotype: voriconazole C<jats:sub>min<\/jats:sub>\/dose ratios of 0.018 (0.1\u00a0mg\u00a0L<jats:sup>\u22121<\/jats:sup>\/5.7\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0day<jats:sup>\u22121<\/jats:sup>), 0.18 (1\u00a0mg\u00a0L<jats:sup>\u22121<\/jats:sup>\/5.7\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0day<jats:sup>\u22121<\/jats:sup>), and 0.23 (2\u00a0mg\u00a0L<jats:sup>\u22121<\/jats:sup>\/8.6\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0day<jats:sup>\u22121<\/jats:sup>) at dexamethasone doses of 20, 12.5, and 2.5\u00a0mg, respectively. Sub-therapeutic voriconazole C<jats:sub>min<\/jats:sub> was associated with high- and moderate-dose dexamethasone (20 and 12.5\u00a0mg), leading to failure of antifungal treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The extent of voriconazole\u2013dexamethasone interaction was determined by the dose of dexamethasone and associated with the <jats:italic>CYP2C19<\/jats:italic> *1*2 genotype. Therapeutic drug monitoring of voriconazole is necessary to avoid clinically relevant interactions for optimal antifungal therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1403966","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:49:20Z","timestamp":1719463760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin\u2019s lymphoma being treated for invasive pulmonary aspergillosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jingjing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.3390\/jcm12227120","article-title":"Drug-drug interactions involving dexamethasone in clinical practice: myth or reality?","volume":"12","author":"Bourdin","year":"2023","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: epidemiology, diagnosis, and treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1128\/aac.04838-14","article-title":"Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels","volume":"59","author":"Gautier-Veyret","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/00498254.2021.1969481","article-title":"Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies","volume":"51","author":"Huang","year":"2021","journal-title":"Xenobiotica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e12886","DOI":"10.1111\/tid.12886","article-title":"Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients","volume":"20","author":"Imataki","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jac\/dkab412","article-title":"Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV","volume":"77","author":"Jacobs","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"666296","DOI":"10.3389\/fphar.2021.666296","article-title":"Interactive effects of glucocorticoids and cytochrome P450 polymorphisms on the plasma trough concentrations of voriconazole","volume":"12","author":"Jia","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/infdis\/jiab163","article-title":"Navigating the uncertainties of COVID-19-associated aspergillosis: a comparison with influenza-associated aspergillosis","volume":"224","author":"Lamoth","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1242711","DOI":"10.3389\/fgene.2023.1242711","article-title":"The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals","volume":"14","author":"Li","year":"2023","journal-title":"Front. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/1120009x.2018.1506693","article-title":"Assessment of drug-drug interactions between voriconazole and glucocorticoids","volume":"30","author":"Li","year":"2018","journal-title":"J. Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/dmr-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metab. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","article-title":"Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes","volume":"73","author":"Murayama","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"ii27","DOI":"10.1093\/jac\/dkz041","article-title":"Diagnosis and treatment of invasive fungal infections: looking ahead","volume":"74","author":"Sanguinetti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1177\/1078155218783248","article-title":"Significant drug interaction between voriconazole and dexamethasone: a case report","volume":"25","author":"Taghvaye","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-asian and asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/jcpt.12401","article-title":"Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature","volume":"41","author":"Wallace","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"106692","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:49:23Z","timestamp":1719463763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":27,"alternative-id":["10.3389\/fphar.2024.1403966"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1403966","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"article-number":"1403966"}}